​

Funding Round

Series B - Aeglea BioTherapeutics

Series B - Aeglea BioTherapeutics

Investment Firm

Overview

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Announced Date

Mar 23, 2015

Closed on Date

Mar 23, 2015

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a early_stage_venture and late_stage_venture and post_ipo and seed firm.

Lilly Ventures

Lilly Ventures

Lilly Ventures is a convertible_note and early_stage_venture and late_stage_venture and seed firm.

Participant Investors

10

Investor Name
Participant InvestorRA Capital Management
Participant InvestorOrbiMed
Participant InvestorNew Ground Ventures
Participant InvestorNovartis Venture Fund
Participant InvestorVenrock

Round Details and Background

Aeglea BioTherapeutics raised $44000000 on 2015-03-23 in Series B

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 22, 2023
Post-IPO Equity - Aeglea BioTherapeutics
-210.0M
Mar 23, 2015
Series B - Aeglea BioTherapeutics
11-44.0M
Feb 06, 2014
Series A - Aeglea BioTherapeutics
4-12.0M

Recent Activity

There is no recent news or activity for this profile.